Stress granule assembly represents a therapeutic vulnerability in super-enhancer-driven circMLB-mediated glioblastoma temozolomide resistance
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2026.218601 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Ruixiang Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, 678 Fu Rong Road, Hefei, Anhui Province, 230601, China; Insti…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Alkylating, Brain Neoplasms, Drug Resistance, Neoplasm, Glioblastoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 78 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Anhui Provincial Department of Education, Anhui Medical University.
Abstract (Originalsprache)
Resistance to temozolomide (TMZ) is a major driver of treatment failure and high mortality in patients with glioblastoma (GBM). However, the mechanisms underlying TMZ resistance, especially intrinsic resistance, remain incompletely elucidated. Through integrative multi-omics analyses, we identified a novel super-enhancer-driven circular RNA, circMLB, which is highly overexpressed in TMZ-R GBM. Both in vitro and in vivo studies robustly demonstrate that circMLB significantly enhances TMZ resistance in GBM. Mechanistically, the transcription factor PAF1 forms a protein complex with BRD4 that is enriched in the super-enhancer region, thereby upregulating circMLB expression. Furthermore, highly expressed circMLB directly binds to PKR, triggering stress granule assembly and ultimately reinforcing TMZ resistance in GBM. Importantly, we identified a novel PKR inhibitor, lurasidone, which synergizes with TMZ to exert potent anti-tumor activity against TMZ-R GBM in preclinical models. Our findings uncover a previously unrecognized SE-circMLB-PKR axis mediating intrinsic TMZ resistance and highlight the lurasidone-TMZ combination as a promising therapeutic strategy to surmount TMZ resistance in GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, 678 Fu Rong Road, Hefei, Anhui Province, 230601, China; Institute of Orthopaedics, Research Center for Translational Medicine, The…
- Department of Neurosurgery, The Second Affiliated Hospital of Anhui Medical University, 678 Fu Rong Road, Hefei, Anhui Province, 230601, China.
- School of Pharmacy, Anhui Medical University, Hefei, 230032, China.
- Department of Neurosurgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.
- Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China; Hefei Cancer Hospital…
Förderung
- National Natural Science Foundation of China
- Anhui Provincial Department of Education
- Anhui Medical University
Zitieren
APA
Huang, R., Yang, Z., Dong, Y., Liang, M., Chen, T., Xie, H., Liu, J., Jiang, Y., Tian, D., & Bian, E. (2026). Stress granule assembly represents a therapeutic vulnerability in super-enhancer-driven circMLB-mediated glioblastoma temozolomide resistance. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218601
Vancouver
Huang R, Yang Z, Dong Y, Liang M, Chen T, Xie H, et al. Stress granule assembly represents a therapeutic vulnerability in super-enhancer-driven circMLB-mediated glioblastoma temozolomide resistance. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218601
BibTeX
@article{Huang2026,
author = {Huang, Ruixiang and Yang, Zhihao and Dong, Yongfei and Liang, Mengxia and Chen, Tao and Xie, Han and Liu, Jun and Jiang, Yanyi and Tian, Dasheng and Bian, Erbao},
title = {Stress granule assembly represents a therapeutic vulnerability in super-enhancer-driven circMLB-mediated glioblastoma temozolomide resistance},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2026.218601}
}
EUVIMED